<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646799</url>
  </required_header>
  <id_info>
    <org_study_id>184BE18012</org_study_id>
    <nct_id>NCT03646799</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 10/1000 mg and D484 10/1000mg in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the&#xD;
      Pharmacokinetics and Safety/Tolerability after Oral Administration of CKD-387 10/1000 mg and&#xD;
      D484 10/1000mg in Healthy Adults&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">August 30, 2018</start_date>
  <completion_date type="Anticipated">September 14, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Dapagliflozin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Maximum plasma concentration of Dapagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Metformin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Maximum plasma concentration of Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Dapagliflozin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of Dapagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Metformin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of Metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Dapagliflozin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity concentration of Dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Metformin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity concentration of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Dapagliflozin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Time to maximum plasma concentration of Dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Metformin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Time to maximum plasma concentration of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Dapagliflozin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Half-life of Dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Metformin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Half-life of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Dapagliflozin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Apparent volume of distribution of Dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Metformin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Apparent volume of distribution of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Dapagliflozin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Apparent clearance of Dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Metformin</measure>
    <time_frame>Predose(0h), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, and 48 hour after drug administration</time_frame>
    <description>Apparent clearance of Metformin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Type II Diabetes</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 1 tablet of reference drug(D484) Period 2: 1 tablet of test drug(CKD-387)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 1 tablet of test drug(CKD-387) Period 2: 1 tablet of reference drug(D484)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-387</intervention_name>
    <description>test drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D484</intervention_name>
    <description>reference drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers between the ages of 19 and 55&#xD;
&#xD;
          -  Body weight ≥ 55kg for male, ≥ 50kg for female&#xD;
&#xD;
          -  Body mass index ≥ 18.5 kg/m2 and &lt; 25.0 kg/m2&#xD;
&#xD;
          -  Females who are post-menopausal or underwent sterilization&#xD;
&#xD;
          -  Males who agreed to practice contraception until after 28 days of last intake&#xD;
             Investigational product&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with clinically significant hepatic, renal, nervous, immune, respiratory,&#xD;
             endocrine, hemato-oncology, cardiovascular systemic disease and psychosis disorder&#xD;
&#xD;
          -  Subject who are weak in dehydration or clinically significant dehydration&#xD;
&#xD;
          -  IV injecting examination of radioactive-iodine substances within 48 hours prior to&#xD;
             first IP administration&#xD;
&#xD;
          -  Subjects who have Galactose intolerance, Lapp lactase deficiency, glucose-galactose&#xD;
             malabsorption&#xD;
&#xD;
          -  Subjects with history of gastrointestinal disease or surgery that may affect&#xD;
             absorption of IP&#xD;
&#xD;
          -  Hypersensitive to dapagliflozin/metformin&#xD;
&#xD;
          -  At screening,&#xD;
&#xD;
               -  AST(Aspartate Transaminase), ALT(Alanine Transaminase) &gt; UNL(upper normal&#xD;
                  limit)*1.25&#xD;
&#xD;
               -  Total Bilirubin &gt; UNL(upper normal limit)*1.5, CPK &gt; UNL(upper normal limit)*1.5&#xD;
&#xD;
               -  eGFR(estimated Glomerular Filtration Rate) &lt; 60 mL/min/1.73m2(Modification of&#xD;
                  diet in renal Disease calculated)&#xD;
&#xD;
               -  Positive reaction on following tests: Hepatitis B, Hepatitis C, HIV(Human&#xD;
                  Immunodeficiency Virus) and syphilis&#xD;
&#xD;
               -  SBP(Systolic blood pressure) ≥ 150 mmHg or &lt; 90 mmHg, DBP(Diastolic blood&#xD;
                  pressure) &gt; 100 mmHg or &lt; 50 mmHg&#xD;
&#xD;
          -  History of drug abuse or positive urine drug screening results&#xD;
&#xD;
          -  Women with pregnant, breast-feeding&#xD;
&#xD;
          -  Caffeine &gt; 5 cups/day, Alcohol &gt; 210 g/week, Smoker &gt; 10 cigarettes /day or who are&#xD;
             unable to stop caffeine intake, drinking alcohol and smoking until the last blood&#xD;
             drawing for PK&#xD;
&#xD;
          -  Subject who took ethical drug/herbal compound within 14 days, over-the-counter&#xD;
             drug/vitamin supplements within 7 days and depot injection/implantation within 30 days&#xD;
             prior to the first IP administration&#xD;
&#xD;
          -  Subject who was enrolled in another clinical trial(including Bioequivalence study) and&#xD;
             administered drugs within 90 days prior to the first IP administration&#xD;
&#xD;
          -  Subject with whole blood donation within 60 days or component blood donation within 30&#xD;
             days&#xD;
&#xD;
          -  Not eligible to participate for the study at the discretion of Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Soo Park, Ph.D.</last_name>
    <phone>82-2-2228-0270</phone>
    <email>minspark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Soo Park, Ph.D. M.D</last_name>
      <phone>+82 2 2228 0400</phone>
      <email>minspark@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Min Soo Park, Ph.D. M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

